A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact

PLoS Med. 2016 May 31;13(5):e1002031. doi: 10.1371/journal.pmed.1002031. eCollection 2016 May.


In a Perspective accompanying Hill and colleagues, Elliot Marseille and James Kahn compare the history of pricing and availability of ART for HIV with that of the new HCV drugs and discuss strategies for providing treatment in LMIC even in the face of high costs.

Publication types

  • Comment

MeSH terms

  • Antiviral Agents / economics*
  • Antiviral Agents / therapeutic use
  • Hepatitis C / drug therapy
  • Hepatitis C / economics*
  • Humans


  • Antiviral Agents